High levels of neutralizing IL‐6 autoantibodies in 0.1% of apparently healthy blood donors
Open Access
- 11 October 2004
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 34 (11) , 3267-3275
- https://doi.org/10.1002/eji.200425268
Abstract
IL‐6‐specific autoantibodies (aAb‐IL‐6) have been reported in diseased and healthy individuals. We recently established a model for aAb‐IL‐6 in different mouse strains, based on vaccination with immunogenic IL‐6 analogues, in which titers of aAb‐IL‐6 above 1,000 resulted in an in vivo IL‐6 deficiency. Here, we examined aAb‐IL‐6 in 4,230 blood donors. Stable low titers of aAb‐IL‐6 were found in 9% of the donors, while 1% had titers ranging from 64 to greater than 10,000. Such aAb‐IL‐6‐positive donors appeared normal with no overt signs of pathology. Natural and recombinant forms of IL‐6 bound avidly to their IgG, and their plasma strongly neutralized IL‐6 in vitro. Slightly elevated concentrations of IL‐6 exclusively in the form of IL‐6‐IgG complexes were present in their circulation. The complexes did not contain soluble IL‐6 receptors. Titers of 0.1% of the blood donors were as positive as the vaccination‐induced IL‐6‐deficient mice. Such donors might be IL‐6 deficient, and if so, IL‐6 seems be dispensable for several months in otherwise healthy individuals. Such highly positive donors also explain why normal human IgG for pharmaceutical use may contain high anti‐IL‐6 activity. Finally, transfusion of plasma with a high titer of aAb‐IL‐6 might, temporally, render a recipient IL‐6 deficient.Keywords
This publication has 27 references indexed in Scilit:
- Knocking out IL‐6 by vaccinationEuropean Journal of Immunology, 2003
- Autoantibodies against granulocyte colony‐stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosusArthritis & Rheumatism, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?Annual Review of Immunology, 2001
- Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonistNature Biotechnology, 1997
- Anti‐Interleukin‐6 Autoantibodies in Plasma are Associated with an Increased Frequency of Infections and Increased Mortality of Patients with Alcoholic CirrhosisScandinavian Journal of Immunology, 1996
- Influence of interleukin‐6 (IL‐6) autoantibodies on IL‐6 binding to cellular receptorsEuropean Journal of Immunology, 1995
- Immunomodulating IL-6 activity by murine monoclonal antibodiesInternational Journal of Immunopharmacology, 1995
- Impaired immune and acute-phase responses in interleukin-6-deficient miceNature, 1994
- High amounts of circulating interleukin (IL)‐6 in the form of monomeric immune complexes during anti‐IL‐6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivoEuropean Journal of Immunology, 1992